bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.
| Author | |
|---|---|
| Abstract | :
Nicotinic acetylcholine receptors (nAChRs) containing α6β2 subunits expressed by dopamine neurons regulate nicotine-evoked dopamine release. Previous results show that the α6β2* nAChR antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) inhibits nicotine-evoked dopamine release from dorsal striatum and decreases nicotine self-administration in rats. However, overt toxicity emerged with repeated bPiDDB treatment. The current study evaluated the preclinical pharmacology of a bPiDDB analogue. |
| Year of Publication | :
2011
|
| Journal | :
British journal of pharmacology
|
| Volume | :
163
|
| Issue | :
2
|
| Number of Pages | :
346-57
|
| ISSN Number | :
0007-1188
|
| URL | :
https://doi.org/10.1111/j.1476-5381.2011.01220.x
|
| DOI | :
10.1111/j.1476-5381.2011.01220.x
|
| Short Title | :
Br J Pharmacol
|
| Download citation |